| | | | | | | | | | | | | | | | |
| |
| Issue Date FY: 2024 ( Subtotal = $284,405 ) |
| 2024 | 2024 | CENTRE FOR ADDICTION AND MENTAL HEALTH | 1001 QUEEN ST W | TORONTO | ON | | | CAN | R01AA028224 | Evaluation of the impact of alcohol control policies on morbidity and mortality in Lithuania and other Baltic states | 000 | 5 | NIH | 4/15/2024 | $402,548 |
| 2024 | 2024 | CENTRE FOR ADDICTION AND MENTAL HEALTH | 1001 QUEEN ST W | TORONTO | ON | | | CAN | R01MH121520 | Neural mechanisms of perceptual abnormalities and their malleability in bodydysmorphic disorder | 000 | 4 | NIH | 11/29/2023 | $118,252 |
| 2024 | 2023 | CENTRE FOR ADDICTION AND MENTAL HEALTH | 1001 QUEEN ST W | TORONTO | ON | | | CAN | R01MH112815 | Confirmatory Safety and Efficacy Trial of Magnetic Seizure Therapy for Depression | 001 | 5 | NIH | 4/15/2024 | $0 |
| 2024 | 2023 | CENTRE FOR ADDICTION AND MENTAL HEALTH | 1001 QUEEN ST W | TORONTO | ON | | | CAN | R01MH112815 | Confirmatory Safety and Efficacy Trial of Magnetic Seizure Therapy for Depression | 000 | 5 | NIH | 11/6/2023 | $0 |
| 2024 | 2023 | CENTRE FOR ADDICTION AND MENTAL HEALTH | 1001 QUEEN ST W | TORONTO | ON | | | CAN | R21DA057542 | Concurrent substance use and psychiatric disorders: a pipeline to investigate shared genomic liability and causal effects | 000 | 1 | NIH | 12/5/2023 | $0 |
| 2024 | 2022 | CENTRE FOR ADDICTION AND MENTAL HEALTH | 1001 QUEEN ST W | TORONTO | ON | | | CAN | R61MH120188 | Neuromodulation of Social Cognitive Circuitry in People with Schizophrenia Spectrum Disorders | 000 | 2 | NIH | 1/19/2024 | -$236,395 |
| 2024 | 2022 | CENTRE FOR ADDICTION AND MENTAL HEALTH | 1001 QUEEN ST W | TORONTO | ON | | | CAN | R01MH115014 | Neuroimaging MAO-B in Medication Free and Treatment Resistant Major Depressive Disorder Using Novel MAO-B Tracer [11C]SL2511.88 | 000 | 5 | NIH | 10/31/2023 | $0 |
| 2024 | 2022 | CENTRE FOR ADDICTION AND MENTAL HEALTH | 1001 QUEEN ST W | TORONTO | ON | | | CAN | R21EB030851 | Personalized 3D avatar tool development for measurement of body perception across gender identities | 000 | 3 | NIH | 4/18/2024 | $0 |
| 2024 | 2021 | CENTRE FOR ADDICTION AND MENTAL HEALTH | 1001 QUEEN ST W | TORONTO | ON | | | CAN | R21MH119496 | RISE Study ("Resist, Intervene, Support, Empower"): Feasibility/Acceptability of MHealth Intervention targeting Transgender Women facing gender-based violence and mental health disorders in Brazil | 000 | 2 | NIH | 3/7/2024 | $0 |
| 2024 | 2020 | CENTRE FOR ADDICTION AND MENTAL HEALTH | 1001 QUEEN ST W | TORONTO | ON | | | CAN | R21AA026680 | Investigating astrocyte status in alcohol use disorder with the novel positron emission tomography (PET) tracer [11C]SL25.1188. | 000 | 2 | NIH | 4/4/2024 | $0 |
| 2024 | 2019 | CENTRE FOR ADDICTION AND MENTAL HEALTH | 1001 QUEEN ST W | TORONTO | ON | | | CAN | R21DA045296 | Understanding Cannabis Withdrawal: A PET Study of Endocannabinoid Metabolism | 000 | 2 | NIH | 1/23/2024 | $0 |
|
| Issue Date FY: 2023 ( Subtotal = $3,723,048 ) |
| 2023 | 2023 | CENTRE FOR ADDICTION AND MENTAL HEALTH | 1001 QUEEN ST W | TORONTO | ON | | | CAN | R21MH128815 | Exogenous Modulation of Visual Perception And Connectivity in Body Dysmorphic Disorder (EMPAC-BDD) | 001 | 2 | NIH | 7/24/2023 | $0 |
| 2023 | 2023 | CENTRE FOR ADDICTION AND MENTAL HEALTH | 1001 QUEEN ST W | TORONTO | ON | | | CAN | R21DA057542 | Concurrent substance use and psychiatric disorders: a pipeline to investigate shared genomic liability and causal effects | 000 | 1 | NIH | 9/1/2023 | $143,441 |
| 2023 | 2023 | CENTRE FOR ADDICTION AND MENTAL HEALTH | 1001 QUEEN ST W | TORONTO | ON | | | CAN | R01MH112815 | Confirmatory Safety and Efficacy Trial of Magnetic Seizure Therapy for Depression | 001 | 5 | NIH | 5/1/2023 | $1,421,655 |
| 2023 | 2023 | CENTRE FOR ADDICTION AND MENTAL HEALTH | 1001 QUEEN ST W | TORONTO | ON | | | CAN | R21MH128815 | Exogenous Modulation of Visual Perception And Connectivity in Body Dysmorphic Disorder (EMPAC-BDD) | 000 | 2 | NIH | 7/21/2023 | $136,369 |
| 2023 | 2023 | CENTRE FOR ADDICTION AND MENTAL HEALTH | 1001 QUEEN ST W | TORONTO | ON | | | CAN | R01AA028009 | A microsimulation of alcohol control interventions to advance health equity and reverse the current decrease in life expectancy in the US | 000 | 4 | NIH | 7/25/2023 | $468,922 |
| 2023 | 2023 | CENTRE FOR ADDICTION AND MENTAL HEALTH | 1001 QUEEN ST W | TORONTO | ON | | | CAN | R01AA028009 | A microsimulation of alcohol control interventions to advance health equity and reverse the current decrease in life expectancy in the US | 001 | 4 | NIH | 7/26/2023 | $106,854 |
| 2023 | 2023 | CENTRE FOR ADDICTION AND MENTAL HEALTH | 1001 QUEEN ST W | TORONTO | ON | | | CAN | R01AA028224 | Evaluation of the impact of alcohol control policies on morbidity and mortality in Lithuania and other Baltic states | 001 | 4 | NIH | 9/19/2023 | $106,949 |
| 2023 | 2023 | CENTRE FOR ADDICTION AND MENTAL HEALTH | 1001 QUEEN ST W | TORONTO | ON | | | CAN | R01AA028224 | Evaluation of the impact of alcohol control policies on morbidity and mortality in Lithuania and other Baltic states | 000 | 4 | NIH | 3/30/2023 | $358,829 |
| 2023 | 2023 | CENTRE FOR ADDICTION AND MENTAL HEALTH | 1001 QUEEN ST W | TORONTO | ON | | | CAN | R01MH121520 | Neural mechanisms of perceptual abnormalities and their malleability in bodydysmorphic disorder | 000 | 4 | NIH | 6/5/2023 | $478,980 |
| 2023 | 2022 | CENTRE FOR ADDICTION AND MENTAL HEALTH | 1001 QUEEN ST W | TORONTO | ON | | | CAN | R21CA260823 | Simulating the impact of a menthol ban in the US; translating the Canadian model | 000 | 1 | NIH | 10/26/2022 | $0 |
| 2023 | 2021 | CENTRE FOR ADDICTION AND MENTAL HEALTH | 1001 QUEEN ST W | TORONTO | ON | | | CAN | R01MH112815 | Confirmatory Safety and Efficacy Trial of Magnetic Seizure Therapy for Depression | 000 | 4 | NIH | 12/7/2022 | $0 |
| 2023 | 2021 | CENTRE FOR ADDICTION AND MENTAL HEALTH | 1001 QUEEN ST W | TORONTO | ON | | | CAN | R21MH119496 | RISE Study ("Resist, Intervene, Support, Empower"): Feasibility/Acceptability of MHealth Intervention targeting Transgender Women facing gender-based violence and mental health disorders in Brazil | 000 | 2 | NIH | 9/26/2023 | $0 |
| 2023 | 2021 | CENTRE FOR ADDICTION AND MENTAL HEALTH | 1001 QUEEN ST W | TORONTO | ON | | | CAN | UH3AA026212 | Enhancing HIV Pre-Exposure Prophylaxis (PrEP) by Targeting Hazardous Alcohol Use and Concurrent Conditions | 000 | 5 | NIH | 8/22/2023 | $0 |
| 2023 | 2021 | CENTRE FOR ADDICTION AND MENTAL HEALTH | 1001 QUEEN ST W | TORONTO | ON | | | CAN | R01MH114879 | Social Processes Initiative in Neurobiology of Autism-spectrum and Schizophrenia-spectrum Disorders(SPIN-ASD) | 000 | 4 | NIH | 2/3/2023 | $0 |
| 2023 | 2021 | CENTRE FOR ADDICTION AND MENTAL HEALTH | 1001 QUEEN ST W | TORONTO | ON | | | CAN | R01MH114970 | 1/5 Neurocognitive and neuroimaging biomarkers: predicting progression towards dementia in patients with treatment-resistant late-life depression | 000 | 5 | NIH | 7/14/2023 | $0 |
| 2023 | 2020 | CENTRE FOR ADDICTION AND MENTAL HEALTH | 1001 QUEEN ST W | TORONTO | ON | | | CAN | R21AA026680 | Investigating astrocyte status in alcohol use disorder with the novel positron emission tomography (PET) tracer [11C]SL25.1188. | 000 | 2 | NIH | 1/24/2023 | $0 |
| 2023 | 2020 | CENTRE FOR ADDICTION AND MENTAL HEALTH | 1001 QUEEN ST W | TORONTO | ON | | | CAN | R01MH115953 | The SenDep Study: Linking Molecular Senescence Changes to Depression and Cognitive Impairment in Late Life | 003 | 2 | NIH | 2/3/2023 | $405,522 |
| 2023 | 2019 | CENTRE FOR ADDICTION AND MENTAL HEALTH | 1001 QUEEN ST W | TORONTO | ON | | | CAN | R21AA026035 | Role of Histamine H3 Receptors on Alcohol Responses | 000 | 2 | NIH | 2/6/2023 | $0 |
| 2023 | 2019 | CENTRE FOR ADDICTION AND MENTAL HEALTH | 1001 QUEEN ST W | TORONTO | ON | | | CAN | R01MH115953 | The SenDep Study: Linking Molecular Senescence Changes to Depression and Cognitive Impairment in Late Life | 002 | 1 | NIH | 2/3/2023 | $98,853 |
| 2023 | 2019 | CENTRE FOR ADDICTION AND MENTAL HEALTH | 1001 QUEEN ST W | TORONTO | ON | | | CAN | R01AA024341 | Neuropharmacological mechanisms of stress-induced relapse to alcohol | 000 | 5 | NIH | 10/19/2022 | $0 |
| 2023 | 2018 | CENTRE FOR ADDICTION AND MENTAL HEALTH | 1001 QUEEN ST W | TORONTO | ON | | | CAN | R21DA043949 | Effects of rTMS on Cannabis Use and Cognitive Outcomes in Schizophrenia | 000 | 2 | NIH | 2/2/2023 | -$3,326 |
|
| Issue Date FY: 2022 ( Subtotal = $2,263,606 ) (Continued on the next page) |
| 2022 | 2022 | CENTRE FOR ADDICTION AND MENTAL HEALTH | 1001 QUEEN ST W | TORONTO | ON | | | CAN | R01MH115014 | Neuroimaging MAO-B in Medication Free and Treatment Resistant Major Depressive Disorder Using Novel MAO-B Tracer [11C]SL2511.88 | 001 | 5 | NIH | 3/22/2022 | $0 |
| 2022 | 2022 | CENTRE FOR ADDICTION AND MENTAL HEALTH | 1001 QUEEN ST W | TORONTO | ON | | | CAN | R21CA260823 | Simulating the impact of a menthol ban in the US; translating the Canadian model | 001 | 1 | NIH | 9/15/2022 | -$202,611 |
| 2022 | 2022 | CENTRE FOR ADDICTION AND MENTAL HEALTH | 1001 QUEEN ST W | TORONTO | ON | | | CAN | R21CA260823 | Simulating the impact of a menthol ban in the US; translating the Canadian model | 001 | 1 | NIH | 9/15/2022 | $202,611 |
| 2022 | 2022 | CENTRE FOR ADDICTION AND MENTAL HEALTH | 1001 QUEEN ST W | TORONTO | ON | | | CAN | R21CA260823 | Simulating the impact of a menthol ban in the US; translating the Canadian model | 000 | 1 | NIH | 9/15/2022 | $202,611 |
| 2022 | 2022 | CENTRE FOR ADDICTION AND MENTAL HEALTH | 1001 QUEEN ST W | TORONTO | ON | | | CAN | R21MH128815 | Exogenous Modulation of Visual Perception And Connectivity in Body Dysmorphic Disorder (EMPAC-BDD) | 000 | 1 | NIH | 6/29/2022 | $136,369 |
| 2022 | 2022 | CENTRE FOR ADDICTION AND MENTAL HEALTH | 1001 QUEEN ST W | TORONTO | ON | | | CAN | R21EB030851 | Personalized 3D avatar tool development for measurement of body perception across gender identities | 002 | 3 | NIH | 8/23/2022 | $120,174 |
| 2022 | 2022 | CENTRE FOR ADDICTION AND MENTAL HEALTH | 1001 QUEEN ST W | TORONTO | ON | | | CAN | R21MH123849 | Multimodal monitoring and high-dimensional data for episode prediction in bipolar disorder | 000 | 2 | NIH | 3/22/2022 | $125,486 |
| 2022 | 2022 | CENTRE FOR ADDICTION AND MENTAL HEALTH | 1001 QUEEN ST W | TORONTO | ON | | | CAN | R01AA028009 | A microsimulation of alcohol control interventions to advance health equity and reverse the current decrease in life expectancy in the US | 001 | 3 | NIH | 9/9/2022 | $109,394 |
| 2022 | 2022 | CENTRE FOR ADDICTION AND MENTAL HEALTH | 1001 QUEEN ST W | TORONTO | ON | | | CAN | R01AA028009 | A microsimulation of alcohol control interventions to advance health equity and reverse the current decrease in life expectancy in the US | 000 | 3 | NIH | 7/25/2022 | $461,706 |
| 2022 | 2022 | CENTRE FOR ADDICTION AND MENTAL HEALTH | 1001 QUEEN ST W | TORONTO | ON | | | CAN | R61MH120188 | Neuromodulation of Social Cognitive Circuitry in People with Schizophrenia Spectrum Disorders | 000 | 2 | NIH | 6/3/2022 | $368,514 |
| 2022 | 2022 | CENTRE FOR ADDICTION AND MENTAL HEALTH | 1001 QUEEN ST W | TORONTO | ON | | | CAN | R01AA028224 | Evaluation of the impact of alcohol control policies on morbidity and mortality in Lithuania and other Baltic states | 000 | 3 | NIH | 4/5/2022 | $459,094 |
| 2022 | 2022 | CENTRE FOR ADDICTION AND MENTAL HEALTH | 1001 QUEEN ST W | TORONTO | ON | | | CAN | R01MH121520 | Neural mechanisms of perceptual abnormalities and their malleability in bodydysmorphic disorder | 006 | 3 | NIH | 6/9/2022 | $479,601 |
| 2022 | 2022 | CENTRE FOR ADDICTION AND MENTAL HEALTH | 1001 QUEEN ST W | TORONTO | ON | | | CAN | R01MH115014 | Neuroimaging MAO-B in Medication Free and Treatment Resistant Major Depressive Disorder Using Novel MAO-B Tracer [11C]SL2511.88 | 002 | 5 | NIH | 5/13/2022 | $21,021 |
| 2022 | 2022 | CENTRE FOR ADDICTION AND MENTAL HEALTH | 1001 QUEEN ST W | TORONTO | ON | | | CAN | R01MH115014 | Neuroimaging MAO-B in Medication Free and Treatment Resistant Major Depressive Disorder Using Novel MAO-B Tracer [11C]SL2511.88 | 000 | 5 | NIH | 12/13/2021 | $189,202 |
| 2022 | 2021 | CENTRE FOR ADDICTION AND MENTAL HEALTH | 1001 QUEEN ST W | TORONTO | ON | | | CAN | R01MH112815 | Confirmatory Safety and Efficacy Trial of Magnetic Seizure Therapy for Depression | 000 | 4 | NIH | 5/10/2022 | $0 |
|